Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05609760
Other study ID # FONDEFID19I10120
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 1, 2022
Est. completion date April 30, 2023

Study information

Verified date June 2022
Source Universidad de Concepcion
Contact Rosa L Figueroa, ScD
Phone +56 9 924956932
Email rosa.figueroa@biomedica.udec.cl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

SIMAP is a triple-masked randomised trial aimed at assessing whether an automated system of pictograms associated to medical indications results in better comprehension and adherence of said indications. Adult patients with a recent diagnosis of asthma will be randomised to receive a pictographic depiction of their treatments and recommended interventions or standard communication without assistance from their attending physician. Patients will be followed-up for 60 days using the Asthma Control Questionnaire (ACT). The primary endpoint of this study is the degree of asthma control as assessed by the aforementioned questionnaire. Secondary outcomes include the number of hospitalisations, emergency care unit visits and the need to increase bronchodilator therapy as per current Global Initiative for Asthma guidelines. Outcomes will be analysed under the intention-to-treat principle by a statistician unaware of treatment allocation.


Description:

In this triple-masked randomised trial, adult participants with a recent diagnosis of asthma (<15 days) will be allocated to receive a pictographic depiction of their medical indications or a standard description of said indications. Eligible patients will include those between 18 and 65 years of age with a diagnosis of asthma established by standard clinical recommendations (clinical and spirometric criteria as established by Global Initiative for Asthma - GINA - guidelines) and in whom therapy including a bronchodilator and a controller medication (typically an inhaled steroid) is planned to be initiated. Patients with another cause of bronchial obstruction (such as COPD), those with cognitive or visual impairments that hampers the understanding of pictograms or those with a history of alcoholism or alcohol abuse will be excluded. Patients will be randomised using a permuted block sequence which shall be kept hidden from other investigators. Participants will be followed-up at seven, thirty and sixty-day intervals using the Asthma Control Questionnaire (ACT), which is the primary outcome of this study. Participants, clinical evaluators, analysts and sponsors will be kept unaware of treatment allocation. Secondary endpoints include the inhaler technique, the correct depiction of inhaler medication purpose, the rate of emergency care visits between groups, the rate of hospitalisations between groups and the need to increase bronchodilator therapy during scheduled visits within the trial. All analyses will be conducted using the intention-to-treat principle.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date April 30, 2023
Est. primary completion date February 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Adult patients aged 18 to 65 years with a recent diagnosis of bronchial asthma (<=15 days) based on 2018 Global Initiative For Asthma (GINA) criteria. - Diagnosis substantiated clinically and with consistent spirometry results as established by current GINA guidelines. - Patients who are to initiate bronchodilator treatment, including at least one inhaled corticosteroid and one short-acting bronchodilator. Exclusion Criteria: - Patients presenting obstructive bronchial pathology other than bronchial asthma (chronic obstructive pulmonary disease, mixed states, etc.), - Patients who have participated in the pictogram design phase (Stage 1 of the project), - Patients with a diagnosis of dementia, diagnosis of harmful use of alcohol and other drugs according to the International Classification of Diseases (ICD-10). - Patients with significant ophthalmologic pathology that prevents the use of pictograms. - Patients who do not wish to participate in the project.

Study Design


Intervention

Other:
SIMAP
Pictographic depiction of medical indications alongside standard communication of these recommendations.
Usual Care
Standard communication by medical staff of treatment indications for asthma. An informative leaflet will be delivered as well.

Locations

Country Name City State
Chile Dirección de Administración de Hualpen Hualpen Biobio
Chile Ilustre Municipalidad de San Antonio San Antonio Valparaiso
Chile Dirección de Administración Salud de Talcahuano Talcahuano Biobio
Chile Corporación Municipal de Valparaiso Valparaíso

Sponsors (6)

Lead Sponsor Collaborator
Universidad de Concepcion Comisión Nacional de Investigación Científica y Tecnológica, Dirección de Administración de Salud Municipal de Talcahuano, ILUSTRE MUNICIPALIDAD DE HUALPEN, Servicio de Salud Talcahuano, Universidad de Valparaiso

Country where clinical trial is conducted

Chile, 

References & Publications (5)

Alvear G, Figueroa L, Hurtado G, Moyano L. Evaluación del grado de control del asma en un centro de atención primaria. Un estudio descriptivo. Rev. chil. enferm. respir. 2016; 32 (2): 68-76. Spanish.

Barros IM, Alcantara TS, Mesquita AR, Bispo ML, Rocha CE, Moreira VP, Lyra Junior DP. Understanding of pictograms from the United States Pharmacopeia Dispensing Information (USP-DI) among elderly Brazilians. Patient Prefer Adherence. 2014 Oct 29;8:1493-501. doi: 10.2147/PPA.S65301. eCollection 2014. — View Citation

Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004 Jan;113(1):59-65. doi: 10.1016/j.jaci.2003.09.008. — View Citation

Perez-Yarza EG, Castro-Rodriguez JA, Villa Asensi JR, Garde Garde J, Hidalgo Bermejo FJ; Grupo VESCASI. [Validation of a Spanish version of the Childhood Asthma Control Test (Sc-ACT) for use in Spain]. An Pediatr (Barc). 2015 Aug;83(2):94-103. doi: 10.1016/j.anpedi.2014.10.031. Epub 2014 Dec 30. Spanish. — View Citation

Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, Fleming LJ, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Mortimer K, Pitrez PM, Sheikh A, Yorgancioglu AA, Boulet LP. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Am J Respir Crit Care Med. 2022 Jan 1;205(1):17-35. doi: 10.1164/rccm.202109-2205PP. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Disease Control at 60 days 60 days after randomisation between groups using the Asthma Control Test. 60 days
Primary Disease Control at 30 days Asthma control achieved at 30 days after randomisation between groups using the Asthma Control Test. 30 days
Primary Disease Control at 7 days Asthma control achieved at 7 days after randomisation between groups using the Asthma Control Test. 7 days
Secondary Inhaler technique Proportion of participants displaying a correct inhaler technique between groups. 60 days
Secondary Aerochamber use Proportion of participants using an aerochamber between groups 60 days
See also
  Status Clinical Trial Phase
Recruiting NCT05546931 - Mobile Health Program for Rural Hypertension N/A
Recruiting NCT04316715 - Life-Steps Counseling to Enhance Adherence and Engagement in PrEP Care N/A
Active, not recruiting NCT04602468 - Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) Phase 4
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Enrolling by invitation NCT04676204 - Relationship Between Oral DMT Burden and Adherence in MS
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Completed NCT05168449 - The Impact of Pharmacist-led Mobile Application on Adherence in Chronic Kidney Disease Patients N/A
Active, not recruiting NCT04612088 - Intervention for Multivitamin Adherence on Bariatric Patients N/A
Completed NCT03958331 - Behavioral Economics and Adherence in Teens (BEAT!) N/A
Completed NCT05233644 - Medication Adherence in Heart Failure After Hospitalisation
Completed NCT03837496 - Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors N/A
Recruiting NCT03683966 - MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study
Withdrawn NCT04754867 - Pre-Test of For the Future Self and Smoking Cessation N/A
Recruiting NCT05996094 - Antiretroviral Adherence and Drug-level Monitoring
Not yet recruiting NCT06056037 - Making ART Work Among Brazilian Youth N/A
Completed NCT03842436 - Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use Phase 4
Completed NCT03651596 - Leveraging mHealth Messaging to Promote Adherence in Teens With CKD N/A
Completed NCT03658252 - Efficacy of Targeted Intervention for Topical Steroid Phobia. N/A
Completed NCT03081559 - Improving Engagement in HIV Care for High-risk Women N/A
Recruiting NCT05515497 - BMT4me: Post-HSCT Medication Adherence mHealth App N/A